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Background: The injection pain of microemulsion propofol is frequent and difficult to prevent. This study examined 
the prevention of pain during microemulsion propofol injection by pretreatment with different doses of remifentanil 
or saline, and premixing of lidocaine. 
Methods: One hundred sixty ASA physical status 1-2 adult patients scheduled for elective surgery were enrolled 
into one of four groups (n = 40, in each). The patients received saline (group LS), remifentanil 0.3 μg/kg (group LR 
0.3), remifentanil 0.5 μg/kg (group LR 0.5), or remifentanil 1.0 μg/kg (group LR 1.0), and after 90 seconds received an 
injection of 2 mg/kg microemulsion propofol premixed with lidocaine 40 mg. Pain was assessed on a four­point scale 
during microemulsion propofol injection. 
Results: The incidence of microemulsion propofol­induced pain was significantly lower in the LR 0.3, LR 0.5 and LR 
1.0 groups than in the LS group (37.5%, 12.5% and 10% vs 65%, respectively). The LR 0.5 and LR 1.0 groups showed 
significantly less frequent and intense pain than the LR 0.3 group. However, both incidence and severity of pain were 
not different between LR 0.5 and LR 1.0 groups. 
Conclusions: The combination of remifentanil and lidocaine is effective in alleviating pain associated with a 
microemulsion propofol injection compared with just lidocaine. Remifentanil 0.5 μg/kg had a similar analgesic effect 
compared to the 1.0 μg/kg dose. (Korean J Anesthesiol 2011; 60: 78­82)
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Introduction
    Propofol (2,6­diisopropylphenol), an intravenous hypnotic, 
has gained popularity as an agent for both induction and 
maintenance of anesthesia due to its rapid onset, short duration 
of action, and minimal side effects. The currently used long­
chain triglyceride (LCT) emulsion propofol formulations have 
several drawbacks including inherent emulsion instability, need 
for antimicrobial agents, hyperlipidemia, pancreatitis, and pain 
on injection [1­4]. This has led to the development of improved 
formulations for this compound [5]. 
    A lipid­free microemulsion propofol (Aquafol
Ⓡ; Daewon 
Phar  ma  ceutical, Seoul, Korea) was developed to eliminate 
lipid solvent­related adverse events of LCT emulsion propofol. 
Microemulsion propofol demonstrated similar pharma­
cokinetics and pharmacodynamics to lipid emulsion propofol 
[6]. It has also been reported that microemuslion propofol is 
as effective and safe as lipid emulsion propofol [7]. However, 
microemulsion propofol produces more frequent and severe 
pain upon injection than lipid emulsion propofol and the 
significantly higher incidence and severity of pain on injection 
with microemulsion propofol is associated with a higher aqueous 
free propofol concentration [7,8]. In one study, 70% of patients 
who received microemulsion propofol reported considerable 
pain on injection [8]. 
    There are a number of studies on the pharmacologic and 
nonpharmacologic strategies for the prevention of pain on 
propofol injection. They include premedication [9], cooling 
or diluting of the propofol solution [10,11] and concomitant 
therapies using ketamine [12], local anesthetics [13], 
ondansetron [14], and opioids [15,16]. However, despite various 
methods to reduce propofol injection pain, none of these 
have achieved the complete elimination of pain. Previous 
studies show that multimodal analgesia using different 
analgesic modalities can reduce the incidence and severity 
of propofol injection pain [17­19]. Also, a recent study shows 
that the combination of remifentanil and lidocaine was more 
effective in reducing the incidence of pain upon the injection of 
microemulsion propofol than either treatment alone [20].
    The aim of the present study was to evaluate the effect of a 
combination of pretreatment with different doses of remifen­
tanil and premixing of lidocaine on the incidence and severity 
of microemulsion propofol injection pain in adults undergoing 
elective surgery.
Materials and Methods
    This study received Institutional Review Board approval, and 
informed consent was obtained from each patient. A total of 160 
patients, aged 20 to 65 years, who were scheduled for elective 
surgery with general anesthesia and were American Society of 
Anesthesiologists (ASA) status I and II, were enrolled. Patients 
who had known allergy to any drugs; had renal, hepatic, or 
cardiac problems; had asthma, diabetes mellitus, neurologic 
deficits and psychiatric disorders; required a rapid sequence 
induction; or had received analgesics or sedatives within the 24 
hours previous to enrolment were excluded. 
    The patients were randomly assigned to one of the four groups 
according to the dose of remifentanil using an Excel (Microsoft, 
USA) generated randomization table. The four groups were 
comparable with respect to patient characteristics (Table 1). No 
patient was excluded from the analysis due to complications 
and therefore data for all 160 patients is presented. 
    The patients received saline (LS group, n = 45), remifentanil 
0.3 μg/kg (LR 0.3 group, n = 45), remifentanil 0.5 μg/kg (LR 0.5 
group n = 45), or remifentanil 1.0 μg/kg (LR 1.0, group n = 45) 
over a 30 s period, and 90 s later received an injection of 2 mg/
kg microemulsion propofol premixed with lidocaine 40 mg over 
a 60 s period. Saline and remifentanil were prepared in a 10 ml 
unlabeled syringe by individuals who had not participated in 
the induction of anesthesia. Microemulsion propofol was mixed 
with 2 ml of 2% lidocaine. The patients, anesthesia providers 
and investigators who scored the movements were blinded to 
the treatment group. All study drugs were prepared before the 
injection at room temperature. 
    Before arriving at the operating room, a 20 gauge cannula was 
inserted in the left cephalic vein of the patient’s nondominant 
hand, and its position was confirmed by the free flow of 
Hartmann’s solution infused by gravity. Standard monitoring, 
including noninvasive arterial pressure, ECG, pulse oximetry 
and bispectral index score (BIS) monitoring was applied 
and assessed continuously. Before induction of anesthesia, 
all patients were preoxygenated. After remifentanil or saline 
injection, microemulsion propofol 2 mg/kg was administered 
through the rubber port connected to the intravenous cannula 
without the carrier fluid. The assessment of pain was made 
continuously from the start of the propofol injection to when 
Table 1. Demographic Data of the Patients in This Study 
 
LS
(n = 40)
LR 0.3
(n = 40)
LR 0.5
(n = 40)
LR 1.0 
(n = 40)
Sex (M/F)
Age (yr)
Weight (kg)
Height (cm)
20/20
46 (12)
64.0 (11.1)
164.1 (8.1)
20/20
46 (10)
59.8 (8.9)
163.6 (7.9)
20/20
49 (10)
64.1 (10.3)
163.6 (8.5)
20/20
48 (9)
  62.1 (10.1)
162.6 (6.8)
Values are shown as mean (SD) or number of patients.  There were 
no significant differences between groups. LS: lidocaine 40 mg + 
saline 10 ml, LR 0.3: lidocaine 40 mg + remifentanil 0.3 µg/kg in 10 
ml, LR 0.5: lidocaine 40 mg + remifentanil 0.5 µg/kg in 10 ml, LR 1.0: 
lidocaine 40 mg + remifentanil 1.0 µg/kg in 10 ml.80 www.ekja.org
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patients lost their consciousness. The severity of pain was 
assessed using a four­point scale. Pain manifestation as a verbal 
response accompanied by facial grimacing or withdrawal of arm 
was scored as severe; grimacing or withdrawal not accompanied 
by a verbal response was scored as moderate pain. If severe or 
moderate pain was not observed, the patient was asked whether 
they had any discomfort in the arms; if they answered ‘yes’, this 
was scored as mild pain; if they answered ‘no’, this was scored 
as no pain [21]. After the loss of an eyelash reflex, the patients 
were intubated after administration of rocuronium 0.8 mg/kg. 
Anesthesia was then carried on normally.
    After the remifentanil or saline injection, BIS score was 
checked to subjectively assess the level of consciousness to 
ensure an adequate response to the pain questionnaires. The 
mean arterial pressure and heart rate were recorded before 
injecting the study drug (baseline), after the remifentanil 
injection, and before tracheal intubation. Chest wall rigidity, 
described as transient chest discomfort, was also recorded 
during remifentanil injection. Patients were monitored hourly 
for 24 hours post­surgery by a blinded investigator for adverse 
effects at the injection site such as pain, edema, wheal and flare 
response. 
    Based on previously published data, the incidence of pain on 
injection of microemulsion propofol should be approximately 
70% [8]. A reduction of 30% (from 70% to 40%) in the treatment 
group would be considered clinically important. Therefore, 37 
subjects per group would be needed to decrease this incidence 
to 5% (power 80% and α = 0.05). We assumed a dropout rate of 
10% and so increased the sample size to 40 patients per group. 
    Statistical analyses were performed using SPSS software 
(version 16.0, SPSS Inc., IL, USA). Analyses of variance were 
performed on the demographic data, using the one­way 
ANOVA test and the chi­square test. The chi­square test was 
used to calculate differences between groups in incidence 
of microemulsion propofol­induced pain. Differences in the 
pain scores among the groups were analysed with the Kruskal­
Wallis rank test and Mann­Whitney tests were performed as 
post­hoc test among the groups. P value < 0.05 was considered 
significant. All values are expressed as mean (SD) or absolute 
numbers (%). 
Results
    The overall incidence and intensity of pain during injection of 
microemulsion propofol in the groups is shown in Table 2. The 
incidence of pain from the microemulsion propofol injection 
in the LR 0.3, LR 0.5 and LR 1.0 groups (37.5%, 12.5%, and 10%, 
respectively, P < 0.05) was significantly lower than that in the 
LS group (65%). The incidence of moderate pain disappeared 
completely in the LR 0.3, LR 0.5 and LR 1.0 groups (0%) 
compared with that in the LS group (20%). The LR 0.5 and LR 1.0 
groups showed significantly less frequent and intense pain than 
the LR 0.3. However, there was a similar incidence of injection 
pain in the LR 0.5 and LR 1.0 groups.
    For all subjects, BIS score were above 90 before the micro­
emulsion propofol injection, indicating adequate responses to 
questionnaires. The decrease in HR and MAP before intubation 
was statistically significant in all groups except HR in the LS 
group compared to the baseline value and in the LR 1.0 group 
compared to the LS group. However, the decrease of HR and 
MAP are of no clinical importance (Table 3). None of the 
patients suffered from desaturation or chest wall rigidity during 
the induction of anesthesia. There were no adverse effects 
observed at the injection site in any patient. 
Discussion
    Propofol­induced pain is a common problem and can be 
very distressing to the patient. It has been ranked by American 
anesthesiologists as the seventh most important drawback of 
Table 2. Incidence and Severity of Pain on Propofol Injection
Severity of pain
LS 
(n = 40)
LR 0.3
(n = 40)
LR 0.5
(n = 40)
LR 1.0 
(n = 40)
1 (No pain)
2 (Mild pain)
3 (Moderate pain)
4 (Severe pain)
14 (35)
18 (45)
  8 (20)
0 (0)
25 (62.5)*
15 (37.5)*
0 (0)*
0 (0)
  35 (87.5)*,†
    5 (12.5)*,†
0 (0)*
0 (0)
 36 (90)*,†
   4 (10)*,†
0 (0)*
0 (0)
The values are shown as the number of patients (%). LS: lidocaine 40 
mg + saline 10 ml, LR 0.3: lidocaine 40 mg + remifentanil 0.3 µg/kgin 
10 ml, LR 0.5: lidocaine 40 mg + remifentanil 0.5 µg/kg in 10 ml, LR 
1.0: lidocaine 40 mg + remifentanil 1.0 µg/kg in 10 ml. *P < 0.05 com-
pared to the LS group, 
†P < 0.05 compared to the LR 0.3 group. 
Table 3. Mean Arterial Pressure (MAP) and Heart Rate (HR)
LS 
(n = 40)
LR 0.3
(n = 40)
LR 0.5
(n = 40)
LR 1.0 
(n = 40)
MAP 
    Baseline
    After remifentanil 
    Before intubation
HR
    Baseline
    After remifentanil 
    Before intubation
96 (14)
94 (15)
  83 (13)*
75 (14)
75 (13)
71 (10)
99 (15)
96 (15)
  82 (12)*
75 (16)
76 (18)
  66 (11)*
102 (13)
98 (11)
 81 (7)*
75 (12)
74 (13)
  66 (10)*
97 (14)
93 (15)
   72 (9)*
,†
79 (16)
75 (15)
    63 (8) *,†
Values are shown as mean (SD). Baseline: before intravenous 
injection of the saline or remifentanil, After Remifentanil: after the 
remifentanil or saline injection. LS: lidocaine 40 mg + saline 10 ml, 
LR 0.3: lidocaine 40 mg + remifentanil 0.3 µg/kg in 10 ml, LR 0.5: 
lidocaine 40 mg + remifentanil 0.5 µg/kg in 10 ml, LR 1.0: lidocaine 
40 mg + remifentanil 1.0 µg/kg in 10 ml. *P < 0.05 compared to 
baseline, 
†P < 0.05 compared to the LS group. 81 www.ekja.org
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current clinical anesthesiology [22]. 
    Although the precise mechanism by which propofol induces 
pain at the time of injection has remained unclear, many 
factors that influence pain during propofol injection are known, 
including the speed of injection, speed of IV carrier fluid, and 
the buffering effect of blood [23,24]. Previous studies have 
shown that younger patients, patients with a peripheral IV site, 
female patients in general and female patients at the follicular 
phase of the menstrual cycle are more sensitive to pain on the 
injection of propofol [25,26]. In addition, it has been reported 
that the incidence and severity of pain during propofol injection 
was related to the formulation of propofol [8,27]. 
    In this study, there was a significantly lower incidence and 
intensity of microemulsion propofol injection pain in the 
combination group than in the LS group (P < 0.05). The LR 
0.5 and LR 1.0 groups showed significantly less frequent and 
intense pain than the LR 0.3 group (P < 0.05). There was a 
similar incidence of injection pain in the LR 0.5 and LR 1.0 
groups.
    The most popular method for reducing injection pain is to 
mix lidocaine with propofol. This technique is easy, fast, does 
not affect the physiochemical property of the drug and more 
importantly is associated with a clinically and statistically 
significant reduction in the incidence and severity of pain 
[13,23]. The mechanism of the analgesic effect of lidocaine 
remains unclear, but is generally considered to be by the 
inhibition of the kinnin cascade [23,28] or the dilutional effect 
on propofol [29]. 
    Pretreatment with remifentanil has been reported to reduce 
the incidence and severity of pain during propofol injection 
[15,16]. Similar to other opioids, the action site of remifentanil 
may either be central or peripheral. Previous studies have 
shown that intravenous opioids given as Bier’s block before 
propofol injection failed to show analgesic efficacy [30,31]. 
In this study, the patients received remifentanil and then 
90 seconds later they received the microemulsion propofol 
injection. Thus, the mechanism of the analgesic effect of 
remifentanil may be related mainly to a central effect. 
    However, some patients do not respond well to lidocaine 
mixed with propofol and some patients continue to complain 
even with lidocaine administration. Moreover, the incidence 
of a painful injection of microemulsion propofol mixed with 
lidocaine 40 mg in our study was ~65%. A previous study 
showed that remifentanil was effective in preventing propofol 
injection pain, and should be used at a dose of at least 0.02 
mg for this purpose [15]. However, in a previous study, an 
intravenous remifentanil 0.5 μg/kg pretreatment was not 
effective in alleviating pain associated with a microemulsion 
propofol injection and the incidence of a painful injection was 
90% [20]. As a result, this incidence is unacceptable, which 
lead us to search for a new method. Recent studies show that 
combination therapy using different analgesic modalities can 
reduce the incidence and severity of propofol injection pain 
[17­19]. Also, recent studies revealed that a combination of 
opioids and lidocaine can reduce the incidence and severity 
of propofol injection pain compared to each drug used alone 
in adults [17,32]. In our study, the incidence of pain from 
the microemulsion propofol injection in the LR 0.3, LR 0.5 
and LR 1.0 groups (37.5%, 12.5%, and 10%, respectively) 
was significantly lower than that in the LS group (65%). A 
previous study show that the combination of pretreatment of 
remifentanil (0.35 μg/kg/min) and a premixture of lidocaine 
with propofol (mixture of propofol 1% and lidocaine 1% in a 
10 : 1 ratio) is more effective in reducing the incidence of pain 
on injection of propofol than either treatment alone [32]. Also, 
in this study, the combination of pretreatment of remifentanil 
and premixture of lidocaine with microemulsion propofol was 
more effective in a dose­dependent manner. The mechanism 
of action involved has not been identified, but it is possible that 
remifentanil enhances the analgesic efficacy of the lidocaine 
premixture. Further study elucidating the mechanism of this 
effect is therefore required. 
    Although, the decrease in HR and MAP before intubation 
was statistically significant in all groups except HR in the LS 
group compared to the baseline value, and in the LR 1.0 group 
compared to the LS group, the decrease of HR and MAP were of 
no clinical importance (Table 3). None of the patients suffered 
from desaturation, apnea and chest wall rigidity during the 
induction of anesthesia. For all subjects, BIS score were above 
90, indicating adequate responses to questionnaires. There were 
no adverse effects at the injection site in any patient. 
    These findings should be considered within the context of 
the limitation of this study. First, we did not use higher doses 
of remifentanil. Higher doses of remifentanil would possibly 
produce further reductions in propofol injection pain. This 
will be of clinical benefit if it is not associated with an increase 
in the incidence of complications. Second, a non­treated 
control group was not included in this study. However, because 
microemulsion propofol produces more frequent and severe 
pain upon injection than lipid emulsion propofol, including a 
non­treated arm would not have been ethical. 
    In conclusion, a combination of pretreatment of remifentanil 
with premixture of lidocaine with microemulsion propofol was 
more effective in reducing the incidence of pain on injection 
of microemulsion propofol than just a premixture of lidocaine 
with microemulsion propofol alone. The combination of 
pretreatment of remifentanil 0.5 μg/kg and premixure of 
lidocaine 40 mg had a similar analgesic effect compared to the 
combination of pretreatment of remifentanil 1.0 μg/kg and 
premixure of lidocaine.82 www.ekja.org
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